
SERA
Sera Prognostics Inc.
$3.51
+$0.11(+3.24%)
68
Overall
80
Value
81
Tech
44
Quality
Market Cap
$139.69M
Volume
132.67K
52W Range
$1.37 - $9.13
Target Price
$2.75
Company Overview
| Mkt Cap | $139.69M | Price | $3.51 |
| Volume | 132.67K | Change | +3.24% |
| P/E Ratio | -4.2 | Open | $3.44 |
| Revenue | $77.0K | Prev Close | $3.40 |
| Net Income | $-32.9M | 52W Range | $1.37 - $9.13 |
| Div Yield | N/A | Target | $2.75 |
| Overall | 68 | Value | 80 |
| Quality | 44 | Technical | 81 |
No chart data available
About Sera Prognostics Inc.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Latest News
Sera Prognostics Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SERA | $3.51 | +3.2% | 132.67K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |